14 advisor opinions Base Subscription Required
Cellebrite AI Forecast Summary
Unlock the rating distributions, return ranges and advisor comparison with a Base subscription.
Checking your access...
Browse Free Assets1 Year Ratings & Returns ()
Ratings: 2 Neutral 2 Buy 10 Strong Buy
Returns range: from +3.7% to +36.4%
5 Year Ratings & Returns ()
Ratings: 3 Buy 11 Strong Buy
Returns range: from +65.6% to +194.6%
Calculated from End of Date $12.45
What do advisors disagree on
The decisive analytical debate centers on terminal multiple potential and sales cycle durability. One viewpoint contends that completing corporate redomiciliation to Virginia will immediately re-rate the stock toward premium domestic defense-software multiples above twenty-five times operating cash flow. Opposing analyses argue that structural smartphone encryption updates represent an inescapable operational tax, requiring permanent research expenditure that caps free-cash-flow margins. This divergence will resolve by observing whether net retention holds above one hundred fifteen percent and whether research intensity stabilizes below twenty-six percent of sales through 2027.
Compare all 14 opinions1 Year & 5 Year ratings, targets & returns · Sorted by 5 Year price return
| Advisor | Model | Research | 1 Year | 5 Year | Full Report | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Target date | Rating | Price target | Price return | Target date | Rating | Price target | Price return | ||||
| Sherlock Holmes AI The Whistleblower Framework | Gemini 3.8 Flash | Researcher Mode but Web Search Wasn't Used | $16.99 | +36.4% | $36.68 | +194.6% | Full report | ||||
| J.P. Morgan AI The Titan Framework | Gemini 3.8 Flash | Researcher Mode with Web Search Used | $16.39 | +31.6% | $33.09 | +165.8% | Full report | ||||
| Superintelligence AI The Anthropologist Framework | Gemini 3.8 Flash | Researcher Mode with Web Search Used | $14.66 | +17.8% | $32.85 | +163.9% | Full report | ||||
| Niccolo Machiavelli AI The Insider Framework | Gemini 3.8 Flash | Researcher Mode but Web Search Wasn't Used | $16.39 | +31.7% | $31.25 | +151.0% | Full report | ||||
| Warren Buffett AI The Value Seeker Framework | Gemini 3.8 Flash | Researcher Mode with Web Search Used | $15.66 | +25.8% | $27.40 | +120.1% | Full report | ||||
| Warren Buffett AI The Value Seeker Framework | Gemini 3.8 Flash | Thinker Mode with Web Search Disabled | $13.85 | +11.3% | $25.93 | +108.3% | Full report | ||||
| Ray Dalio AI The Strategist Framework | Gemini 3.8 Flash | Researcher Mode but Web Search Wasn't Used | $14.80 | +18.9% | $25.64 | +105.9% | Full report | ||||
| Michael Burry AI The Vulture Framework | Gemini 3.8 Flash | Researcher Mode with Web Search Used | $14.67 | +17.8% | $25.42 | +104.2% | Full report | ||||
| Universal Investor AI The Polymath Framework | Gemini 3.8 Flash | Thinker Mode with Web Search Disabled | $13.72 | +10.2% | $24.94 | +100.3% | Full report | ||||
| Superintelligence AI The Anthropologist Framework | Gemini 3.8 Flash | Thinker Mode with Web Search Disabled | $13.59 | +9.2% | $24.67 | +98.2% | Full report | ||||
| Universal Investor AI The Polymath Framework | Gemini 3.8 Flash | Researcher Mode but Web Search Wasn't Used | $15.22 | +22.2% | $22.54 | +81.0% | Full report | ||||
| Elon Musk AI The Visionary Framework | Gemini 3.8 Flash | Researcher Mode but Web Search Wasn't Used | $14.39 | +15.6% | $22.38 | +79.8% | Full report | ||||
| Universal Investor AI The Polymath Framework | GPT-6 Astra | Researcher Mode with Web Search Used | $12.91 | +3.7% | $21.02 | +68.8% | Full report | ||||
| Universal Investor AI The Polymath Framework | Claude Opus 5 | Researcher Mode with Web Search Used | $13.17 | +5.8% | $20.62 | +65.6% | Full report | ||||
Prices, dates & return assumptions
1 Year and 5 Year identify the original published checkpoints. Current returns compare the dated close with each fixed target over its remaining horizon. Original quarterly tables use the publication-time anchor. Targets and observed prices share a split-adjusted basis.
Ratings use the shared volatility-adjusted calculation.
Ranges and rating distributions use matching currencies, price bases and target dates. Missing or expired checkpoints are excluded; targets are never extrapolated. Shared frameworks and models can produce correlated opinions.
Cellebrite Stock Analysis & Forecast — Universal Investor The Polymath Framework on Gemini 3.8 Flash Model
Universal Investor AI · The Polymath Framework
5 Year Rating
5 Year Price Return
+81.0%
Framework Description & Key Record Dates
Investment Framework
The Polymath Framework: Eight-Lens Investment Analysis Framework
Analysis Framework Description: Select the lenses with the greatest explanatory power, resolve their disagreements across horizons, and connect the evidence to a consistent thesis, scenario path, and verdict.
- Ownership and value: examine economic rights, competitive advantage, capital allocation, and the price paid.
- Regimes and constraints: connect credit, liquidity, policy, demand, and physical bottlenecks to the asset.
- Innovation and adaptation: test adoption economics, AI and robotics exposure, substitution, and value capture.
- Forensics and incentives: reconcile accounting, cash conversion, dilution, governance, and missing evidence.
- Expectations and reflexivity: distinguish changes in fundamentals from changes in narratives and valuation.
- Probabilities and resilience: use base rates, competing scenarios, catalysts, and the capacity to survive the wait.
- Power and the rules of the game: assess political interests, regulatory influence, protection, and dependency.
- Industry structure and consolidation: identify pricing power, chokepoints, alliances, and the economics of integration.
- Model Producer:
- Model Version:
- Gemini 3.8 Flash
- Mode Used:
- Researcher
- Input Data:
- Input records not available
- Forecast Target Date:
- Latest Known Price Date for Return Estimate Refresh:
- Forecast Published On:
- Forecast Generated On:
- Model knowledge cutoff:
- Supplied Context Data, Prices & Events Cutoff:
- Not recorded
Return calculation details
Current returns use the observed price and remaining time to the fixed published target. The quarterly table retains the original forecast anchor.
Full advisor report Chart, analysis, and sources
Cellebrite: Historical Prices & Published Forecast
Analyzed by The Polymath Framework using the Gemini 3.8 Flash model
- Observed price
- Published advisor forecast
Cellebrite: Quarterly Price Forecasts & Scenarios
Analyzed by The Polymath Framework using the Gemini 3.8 Flash model
Price targets, price returns and complete scenario reasoning
Forecast prices in USD. Price returns are cumulative from the original forecast anchor dated 2026-09-18; they exclude dividends. Swipe horizontally to read every column.
| Quarter | Forecast | Price return | Scenario |
|---|---|---|---|
| $12.32 | +6.0% | Third-quarter results confirm annual recurring revenue within guided ranges as master permit clearance resolves federal deal delays. Restored procurement velocity calms immediate execution fears, driving an initial valuation rebound from oversold post-earnings troughs. | |
| $13.30 | +14.5% | Strong fourth-quarter performance and shareholder approval of the US redomiciliation plan eliminate corporate governance overhang. Accelerated Inseyets migrations lift subscription revenue, prompting sell-side multiple expansion as enterprise contract visibility improves across key accounts. | |
| $14.63 | +25.9% | Completion of the corporate redomicile to Virginia triggers substantial passive institutional accumulation ahead of Russell index inclusion. Domestic corporate status removes federal bidding friction, accelerating sovereign contract awards and expanding operating cash flow. | |
| $15.22 | +31.0% | Second-quarter earnings showcase sustained net retention above 116%, validating pricing power across law enforcement cohorts. Despite broader macroeconomic rate headwinds, expanding Guardian SaaS billings drive robust operating margin expansion and support share prices. | |
| $15.67 | +34.9% | State and municipal law enforcement agencies execute year-end budget appropriations, boosting high-margin software license renewals. Favorable operating leverage cushions ongoing R&D expenditures, delivering steady free cash flow growth that supports moderate equity appreciation. | |
| $16.46 | +41.6% | Full-year 2027 financial disclosures confirm free cash flow surpassing $170 million, driven by disciplined operating expense management. Institutional re-rating accelerates as the market rewards pristine debt-free balance sheets amid persistent global macroeconomic volatility. | |
| $16.95 | +45.9% | Cross-selling of drone forensics and mobile virtualization solutions into NATO defense agencies broadens addressable market penetration. Solid net new ARR generation offsets modest foreign exchange friction, sustaining constructive upward momentum in quoted shares. | |
| $16.61 | +43.0% | Summer procurement seasonality and macro software multiple compression trigger a minor consolidation in equity valuation. Prolonged evaluation cycles for enterprise corporate investigation tools temporarily dampen net new customer additions across commercial sectors. | |
| $17.28 | +48.7% | US federal fiscal year-end budget flush unlocks delayed intelligence agency task orders, reigniting top-line ARR acceleration. Expanding high-margin software renewals boost fourth-quarter cash generation, prompting renewed institutional accumulation across defense-tech portfolios. | |
| $17.80 | +53.1% | Reporting of fiscal 2028 operating results demonstrates sustained adjusted EBITDA margins near thirty percent. The board authorizes a targeted share repurchase program using surplus cash reserves, providing direct per-share earnings accretion and lifting market sentiment. | |
| $18.51 | +59.3% | General release of next-generation Pathfinder predictive analytics drives accelerated enterprise contract conversions. Expanding corporate eDiscovery and internal investigation adoption broadens revenue diversification beyond traditional public safety, driving a sustained valuation multiple expansion. | |
| $18.88 | +62.5% | Mid-year execution reveals stable dollar-based net retention rates near 115% as Inseyets penetration reaches mature levels. Steady subscription compounding offsets minor executive compensation dilution, maintaining modest, predictable period-over-period equity appreciation. | |
| $19.44 | +67.3% | Robust sovereign defense allocations and European public safety upgrades drive strong year-end subscription bookings. High recurring gross margins above eighty-five percent translate top-line billings into substantial fourth-quarter free cash flow, reinforcing share pricing. | |
| $20.2 | +74.0% | Fiscal 2029 earnings release confirms annual recurring revenue approaching $800 million alongside disciplined cost containment. Cash conversion efficiency exceeds management guidance, encouraging institutional dividend and buyback expectations that propel equity valuations higher. | |
| $20.6 | +77.5% | Broad adoption of the Genesis investigative platform across financial crimes units drives incremental high-margin SaaS revenue. International expansion across Asia-Pacific offsets localized budget constraints in secondary markets, maintaining positive valuation drift. | |
| $20.4 | +75.7% | A major smartphone operating system cryptographic patch temporarily impedes extraction velocity, lengthening research turnaround times. The technical bottleneck prompts brief caution among prospective software upgraders, inducing a mild quarterly share price pullback. | |
| $21.0 | +81.0% | Cellebrite Labs deploys proprietary exploit updates, restoring extraction leadership and unlocking deferred enterprise license renewals. Federal year-end contract disbursements reinforce fourth-quarter cash generation, driving an immediate recovery in quoted share valuations. | |
| $21.7 | +86.4% | Fiscal 2030 results confirm ARR crossing $900 million with adjusted EBITDA margins sustaining above thirty percent. Market recognition of Cellebrite's durable public-safety monopoly drives further multiple expansion, lifting the stock toward multi-year valuation highs. | |
| $22.1 | +90.2% | Expansion into specialized tactical edge forensics for allied armed services broadens government contract backlog. Consistent high-margin recurring cash flows and lack of funded debt reinforce premium software valuation multiples across institutional holdings. | |
| $22.5 | +94.0% | Maturing subscription base delivers predictable twenty-eight percent free cash flow margins, supporting expanded capital return programs. Defensive public-safety positioning and unmatched forensic technological moats ensure the stock closes the forecast horizon firmly rerated. |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Cellebrite: Investment Thesis Base Case
Analyzed by The Polymath Framework using the Gemini 3.8 Flash modelInvestigating Cellebrite's financial trajectory indicates that the August 2026 equity liquidation created an attractive mispricing in the shares. The core tension centers on whether delayed US federal orders signal structural market saturation or transient administrative friction. Corroborated evidence—specifically the resolution of the Foreign Entity Permit, the planned corporate redomiciliation to Virginia by early 2027, and resilient net retention rates of 117%—demonstrates that enterprise demand remains robust. As Inseyets adoption deepens and SaaS Guardian deployments expand, operating margins will compound toward thirty percent, driving a steady rerating of Cellebrite's compressed cash-flow multiple.
- Fiscal 2026 annual recurring revenue reaches $556 million, anchoring unencumbered free cash flow generation above $145 million.
- Valuation expands toward an enterprise-value-to-EBITDA multiple of nineteen times, reflecting normalized sovereign procurement velocity and US index eligibility.
- Implied equity valuation converges toward sixteen dollars per share, cross-checked by a sustainable four percent normalized free cash yield.
Cellebrite: Scenarios & Signals
Analyzed by The Polymath Framework using the Gemini 3.8 Flash modelBull Case
Rapid execution of the US redomiciliation by early 2027 activates immediate sovereign defense tailwinds. This corporate shift accelerates large multi-agency federal contract awards, propelling annual recurring revenue growth beyond twenty-two percent. Enhanced operating leverage and soaring Guardian cloud adoption expand adjusted EBITDA margins to thirty-four percent. Investors aggressively reprice the stock to twenty-five times forward EBITDA, driving the quoted share price toward twenty-two dollars per share.
Bear Case
A severe technical deadlock in circumventing upgraded mobile cryptographic architectures paralyzes new Inseyets customer conversions. Slower deal velocity is compounded by prolonged legal proceedings and protracted federal procurement freezes, depressing net retention rates below one hundred and ten percent. Operating deleverage and elevated R&D spending compress free cash flow margins toward fifteen percent. Quoted shares derate toward eight dollars, reflecting a multiple discount for impaired organic growth.
Behavioral Alpha Signals
Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.Expected Volatility Regime: High
Greed and Fear Index: -58 / 100 (Fear)
Cycle Position: Stabilization
The reset is mostly complete and price drifts toward fair value.
What does Media Tell? (Crowd Consensus)
The consensus narrative treats Cellebrite as a busted growth story following its August 2026 ARR miss, lowered full-year guidance, and sudden CEO turnover. Market participants anchor heavily on the 29% post-earnings plunge, interpreting deal slippage as evidence of customer pushback and slowing Inseyets migration. Consensus sells Cellebrite as an execution-impaired vendor rather than recognizing temporary administrative procurement delays.
What Crowds Get Wrong? (Alpha/Value Gap)
The crowd materially underestimates Cellebrite's intrinsic earnings power, creating substantial underpricing. Dissecting the second-quarter disclosure reveals the ARR shortfall stemmed not from competitive loss, but from a four-week Foreign Entity Permit delay already resolved through a master permit. Furthermore, the market ignores that management raised adjusted EBITDA guidance to $156 million midpoint while free cash flow yield approaches five percent. Announcing US redomiciliation dismantles foreign procurement bottlenecks and unlocks domestic institutional index inclusion, an asymmetry the consensus has completely mispriced.
When will Value Gap Repricing Happen? (Repricing Catalyst)
The primary catalyst is the scheduled completion of Cellebrite's corporate redomiciliation to the United States in early 2027. This reorganization directly eliminates federal foreign-entity permit hurdles and unlocks passive institutional capital via Russell 2000 index inclusion. The initial observable confirmation will be a sharp acceleration in fourth-quarter 2026 federal contract bookings.
How is Asset Influenced by Macro Regime?
The prevailing macro regime of higher terminal policy rates and sticky inflation provides a mild headwind for tech valuations. However, Cellebrite operates with negative net debt, high recurring public safety budgets, and robust pricing power, making its cash generation highly resilient to monetary tightening and macro deceleration cycles.
Cellebrite: Positive & Negative Factors, Risks & Opportunities
Analyzed by The Polymath Framework using the Gemini 3.8 Flash modelBase-Case Forces
Top Drivers / Tailwinds
Base-case positive forces
Structural or operating forces that support this advisor thesis. Base-case means above 70% probability of occurrence. Probabilities are model estimates; unquantified forces retain their published group.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| United States Redomiciliation Unlocks PR | Regulatory | +24% | +20% | Investigating the root cause of August's deal slippage reveals Foreign Entity Permit requirements hindered federal cloud adoption. Establishing a domestic US corporate parent by early 2027 removes foreign-vendor clearance friction across DoD and federal agencies. This structural clearance accelerates enterprise contract velocity, unlocks previously restricted sovereign defense funding, and directly expands recurring ARR and operating earnings through high-margin public sector renewals. |
| Inseyets Platform Upgrade Drives Expansi | Competitive Positioning | +22% | +25% | Forensic investigations require unlocking advanced device encryptions where Cellebrite's proprietary Inseyets architecture maintains an undisputed technological moat over open-source and legacy alternatives. Evidence shows customer migration from legacy UFED to Inseyets expands average contract value by twenty to thirty percent. This upgrade cycle steadily lifts net retention rates toward 120%, compounding subscription gross margins above eighty-five percent and expanding terminal cash flows. |
| Structural Expansion IN Federal Defense | Political And Geopolitical | +18% | +16% | Heightened geopolitical fragmentation, drone warfare proliferation, and regional border conflicts systematically increase demand for battlefield digital forensics and encrypted extraction tools. Cellebrite Federal Solutions holds CMMC Level 2 certification, perfectly aligning with heightened procurement mandates across Western allied defense departments. This environment secures durable, multi-year sovereign contract allocations, insulating high-margin recurring software revenue from broader commercial macro cycles and reinforcing earnings compounding. |
| SAAS Margin Expansion AND Operating LEVE | Operational Efficiency | +16% | +22% | Financial scrutiny reveals Cellebrite's shift toward Guardian SaaS and cloud-native investigative workflows structurally dampens physical appliance manufacturing costs. Because research and development and sales infrastructure are largely built out, incremental subscription revenue flows through at seventy percent contribution margins. This operating leverage expands full-year adjusted EBITDA margins beyond thirty percent, converting over twenty-eight percent of top-line revenue into unencumbered free cash flow. |
Top Frictions / Headwinds
Base-case negative forces
Expected frictions that can slow, cap, or damage this advisor thesis. Base-case means above 70% probability of occurrence. Probabilities are model estimates; unquantified forces retain their published group.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Smartphone Operating System Encryption H | Innovation And Product | -15% | -12% | Mobile operating system architects, specifically Apple and Google, continually update cryptographic architectures, hardware enclaves, and zero-click exploit mitigations to thwart physical and logical extractions. This cat-and-mouse dynamic forces Cellebrite to escalate research and development expenditures to maintain exploit efficacy. Delayed research breakthroughs extend customer extraction backlogs, temporarily compress software gross margins, and increase client hesitation during critical annual subscription renewals. |
| Prolonged Public Sector Procurement CYCL | Sector And Industry | -12% | -10% | Government and municipal law enforcement agencies operate under rigid budgetary appropriations and protracted multi-stage compliance approvals. Fiscal tightening and administrative delays routinely push closing timetables for large-scale enterprise deals across quarterly reporting boundaries. This structural friction creates revenue lumpiness, dampens near-term annual recurring revenue predictability, and triggers periodic multiples compression among public software investors hypersensitive to quarterly growth linearity. |
| POST Guidance CUT Shareholder Litigation | Regulatory | -10% | -6.0% | Following the August 2026 guidance revision and abrupt executive transition, class-action litigation investigations from plaintiff law firms introduced persistent legal friction. While commercial fundamentals remain intact, ongoing discovery demands, defense costs, and potential settlement liabilities consume executive bandwidth and capital reserves. This legal overhang suppresses institutional multiple expansion, keeping headline price-to-earnings valuations discounted until formal motions to dismiss or settlements are finalized. |
| Dilution FROM Executive Equity Compensat | Capital Allocation | -8.0% | -5.0% | Proxy disclosures reveal ongoing dilution risks stemming from substantial stock-based compensation programs and newly proposed executive compensation packages following the August 2026 CEO appointment. Cellebrite's historical share pool expansions represent roughly eight to ten percent structural dilution over time. This continuous equity issuance dilutes per-share earnings growth, partially offsetting top-line net income expansion and dampening shareholder per-share free cash flow compounding. |
Risks & Opportunities
Top Risks / Downside Scenarios
Lower-probability downside scenarios outside the base-case forecast.
Unlock the risk analysis
Sign in with eligible access to read risks, opportunities and the remaining advisor reports.